Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the grand opening of a new commercial hub to better serve customers across the Nordic region. The new office, in the Ørestad area of Copenhagen, Denmark, was opened by members of the management team in December 2021.
The new facility represents a major investment in the Nordics region and will ensure additional support for Smith+Nephew sales teams who directly interact with customers on a daily basis. Customer support activities will be centralized in Copenhagen and will benefit from a modern office space with larger scale conference, meeting and training facilities. Smith+Nephew has invested in new central positions that support customers and sales teams better for supply planning and tender support.
In addition to the benefits for Smith+Nephew’s customers, employees will also enjoy a state-of-the-art modern working environment that includes flexible working areas designed around encouraging collaboration (hub spaces), focused work (study spaces) and networking and socialising (club spaces).
The opening ceremony was attended virtually by Chief Executive Officer Roland Diggelmann and Si Tarry, Managing Director, UK, Ireland & Nordics, who commented, “This is so much more than a new office; it is a significant milestone for our Nordic business. Our investment shows how much we believe in this important, growing region and I would like to thank everyone who has played a part in making this happen. I cannot wait to visit the Hub in person when travel restrictions allow.”
To further support customers, in late Spring 2022 Smith+Nephew will also open a new distribution centre in Gothenburg, Sweden, to manage product loans, service and repair across the Nordic region.
Enquiries
| Media |
|
| David Snyder | +1 978-749-1440 |
| Smith+Nephew
|
|
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.